The World Market For Anemia Drugs Market Is Expected Grow Up To Us$21.4 Billion By 2022

Anemia cases are on the rise around the world.  This alarming trend is similar to what has been observed in comparison to other diseases globally. However, many drug companies have taken notice of the problem and are developing drugs and testing them through clinical trials to so as to get them into the market to treat those who have been diagnosed with the condition. Though Anemia is a very common health condition, it is also caused as a side effect reaction to other diseases such as cancer, kidney diseases etc. These anemia cases as relatively untreated and have few drugs that can treat this condition specifically.

Get a sample report at https://www.marketresearchfuture.com/sample_request/2499 .

According to a report published by Market Research Future on Global Anemia Drugs Market Research Report- Forecast to 2022 states that the global market for Anemia Drugs is worth US$21.4 billion and will grow at an estimated CAGR of 8.4% to reach US$34.7 billion at the end of forecast period by 2022.The global market for anemia drugs is demonstrating a good trend of positive growth. Growing awareness and increased investment & interest towards developing drugs to combat this condition are contributing favorably to growth of the market. Since anemia significantly affects the quality of life and has also has been found as a causative factor for reducing the survival rates in cancer related cases.

Since anemia is more prevalent in women than in men, the market is majorly driven by them. Increasing rates of anemia diagnosis in pregnant women and deficiency of iron intake in diets and low levels of iron absorption level are causing expansion of the anemia drug market. Certain types of anemia types will be responsible for shaping the anemia drug industry in the forecast period. Other factors that could possibly contribute to the growth of this market are growing awareness about the condition, increasing emphasis of social healthcare on women healthcare particularly on anemia, escalation in cancer cases and other risk factors such as diabetes, lifestyle induced stress, poor nutritional habits, intestinal infections etc. On the other hand factors that may limit market growth are poor drug absorption rates and better nutrition rates.

Latest Industry News:

April 2017 Akebia Therapeutics, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that they have expanded their collaboration for vadadustat by entering into a collaboration and license agreement for Europe, China and other territories. Under the terms of this collaboration agreement, Akebia will receive $208 million or more in committed capital from Otsuka, including $73 million upon signing and $135 million or more of development funding. The companies are equally sharing the costs of developing and commercializing vadadustat in the U.S., as well as the profits from potential future sales of vadadustat in the billion dollar worth renal anemia market.

Jan 2017 A first-in-class drug for anemia caused by chronic kidney disease (CKD) has been developed by FibroGen and AstraZeneca which has cleared two phase III studies in China and will be filed for approval before the end of 2017.

October 2017 Amgen Inc. has entered in an agreement to buy Kirin-Amgen, its joint venture with Japan-based Kirin Holdings Co., for $780 million. Amgen and Kyowa Hakko Kirin, the biopharmaceutical arm of Kirin, formed the 50-50 partnership in 1984 to develop Epogen, a drug used to promote the growth of red blood cells in patients with anemia.

Browse Complete Report at https://www.marketresearchfuture.com/reports/anemia-drugs-market-2499 .

Global Anemia Drugs Market – Competitive Analysis

With the entry of industry players in the anemia drug segment, a trend of solid, volume-driven growth has been observed in the market with the introduction of various types of drugs for different uses. With companies aiming to capture a considerable share of the market segment as early as possible, they are competing and experimenting with various advantage points. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies.

Some of the key players in this market are Amgen Inc., GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics Inc. Some of the other prominent players are Regen biopharma Inc., Bayer AG, Acceleron Pharma, Eli Lilly and company and others.

Global Anemia Drugs Market – Segments

Global anemia drugs market has been segmented on various basis such as:

On The Basis Of Anemia Type: Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia Pernicious Anemia And Others.

On The Basis Of Route of Administration: Oral and Injectable.

On The Basis Of Gender: Male and Female.

On The Basis Of Product Type: Biologics and Non-Biologics.

On The Basis Of End Users: Hospitals, Self-Administered And Others.

Global Anemia Drugs Market – Regional Analysis

Globally, America is the largest market for anemia drugs followed closely by Europe. However it must be noted that the Asia Pacific region is the fastest growing region and is poised to overtake the developed regions market soon. The Middle East and African market will also witness good growth rates. The chief cause for the greater growth of developing regions market is unmet medical needs and social health schemes launched by governments and other bodies. The awareness towards women health and changes in social conditions is also fuelling the demand for anemic drugs.

More Inquire at https://www.marketresearchfuture.com/enquiry/2499 .

About us

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

P: +1 646 845 9312

W: www.marketresearchfuture.com

sales@marketresearchfuture.com

This release was published on openPR.